Member Info for Newuncle

Rubbish it was clearly a buy and you know it was

And what about the delayed sell 08:06:43 2.9555 234,570 Unknown* 2.80 3.00 6,933

Erebus filtered, suggest others do the same as he is only here to make personal attacks at rias and disrupt the BB.

+20% and over 3p...if it can stay above that then who knows where to next. GL all here

Obviously sacked.

£400k company looking for up to £2m finance.......hmmmm.....if they get it ....they will have to consolidate shares in issue for sure.

Kid

Agreed 2.18% it is, still huge

May be the new coo has gone in big?

My maths suggests buyer bought 2.7% of the company yesterday?

Nice chart W formation chart showing double bottom pattern which can be very bullish if it continues. Early days but for such a small cap company looks good.

Hi Laura very similar yet different expertise that might combine very well. Same addressable markets and maybe clients too. Would be a Powerful pairing imo

Well today was great. Clearly people happy taking decent stakes in what looks a nice small business with plenty of upside potential to be realised during 23/24.....

Laura was that your £80k buy?

Yes an £80k biggy at premium

Ooohhh seen that 3m delayed buy from 11.30 yet?

Laura, hope that helps?

Dr Alastair Smith, Chief Executive of Avacta Group plc commented:

"I believe that we are on the verge of a paradigm shift in how chemotherapy is delivered to cancer patients.

The safety and initial efficacy signals emerging from the data in the AVA6000 Phase 1 study are very encouraging indeed. The pre|CISIONTM platform is doing exactly what it was designed to do - target the release of active chemotherapy to the tumour tissue, sparing healthy tissues and improving the safety and tolerability of the drug whilst delivering potentially superior efficacy.

I'm particularly pleased that, even at this early stage and in this patient group, we have a confirmed, significant response in a patient with soft tissue sarcoma, as well as other positive signals across a number of other patients.

We're now aiming to accelerate the clinical development of AVA6000 and begin the Phase 2 efficacy study earlier than originally planned. The Phase 2 trial will follow a short study to determine the safety and efficacy of fortnightly dosing to allow us to determine the recommended Phase 2 dosing regimen.

I look forward very much to sharing the detailed data from the Phase 1a study in due course."

Getting the doseage right would be a natural fit with PYC tech?

People expect Avacta will be taken out for billions by a major pharma within 12 months fwiw as their solution could be adopted globally and it seems to work based on limited trials to date (based on 6 successful cohorts I believe).

That shows a possible connection with PYC tech might be of interest to Avacta?

Avacta provide a "sugar coated" solution for the doseage of cancer treatments which have been shown that doses and frequency can be increased without harming patients the way that treatments usually do as the treatments can cause serious side effects to the patients well being and some vital organs. The sugar coating effectively prevents this and allows the chemo to target the tumours far more effectively. Trials ongoing

Buying is continuous.....